"the further I look back, the further I can see the future" Dennis McGonagle quoting Winston Churchill to describe his approach to understanding What is New in PsA at #EULAR2026 @eular_org @RheumNow https://t.co/ayInzzb9lO

#EULAR2026 OP0125 It’s a case of “teamwork makes the dream work!” Instead of an index to capture heterogeneity in #Sjogren activity, the NECESSITY validated using data from 16 RCTs that a new composite tool, STAR has high sensitivity & specificity. Vital for use in RCTs @RheumNow https://t.co/ftx1uBP11A

📈 Do SIJ lesions progress in #axSpA? DESIR cohort (n=649, 10yrs): Yes, slowly, but bDMARDs reduce erosion progression #OP0102 #EULAR2026 @RheumNow https://t.co/Ap35q9D6B4

🔍 Best imaging outcome for #axSpA structural change? SPACE cohort (n=332): MRI-SIJ fat lesions most sensitive to change #OP0103 #EULAR2026 @RheumNow https://t.co/His1BGYmEW

🖥️ Can MRI-based synthetic CT detect spinal progression in #axSpA? COPECARE (n=25, 1yr): sCT matches ldCT with no radiation #OP0104 #EULAR2026 @RheumNow https://t.co/pe9wSMXXZQ

🔍 Is #axSpA overdiagnosed locally? IMPROVE-axSpA prosp study (n=969): Yes! Only 54% locally confirmed centrally #OP0105 #EULAR2026 @RheumNow https://t.co/VqCPbbCHLB

🔍Can early TNFi beat step-up csDMARDs in pSpA? SPARTACUS RCT (n=97) says YES 60% vs 33% remission at 24 wks #EULAR2026 @rheumnow #OP0107 https://t.co/1odtcRdTLQ

💉 IXE+TZP beat IXE alone in obese PsA? YES - TOGETHER-PsA RCT 33.5% vs 20.4% ACR50 at week 36 in 271 patients OP069 #EULAR2026 @RheumNow @DrLauraCoates @AlexisOgdie https://t.co/orvAe38alc

🥗 Does diet improve PsA? DIPSA RCT: Mediterranean/DASH/Standard all improved DAPSA in 92pts Weight loss drove outcomes OP070 #EULAR2026 @RheumNow https://t.co/k5y7bvDbDQ

Results of this 10yr ffup study on impact of sex on clinical outcomes & spinal xray prog in SpA: Females ⬆️ dse act (asdas,basdai) ⬆️enthesitis scores, S/TJCts Males ⬆️rate of xray prog(msasss) Sex diffs exist in SpA Need for sex-specific mgt AbsOP0101 @Rheumnow #EULAR2026 https://t.co/qiNzDFh08v

#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua

The first two days of EULAR 2026 have delivered a flood of new data, late-breaking science, and clinical insights. Don't spend hours sorting through hundreds of abstracts; RheumNow will do it for you. Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty as they break down the https://t.co/eAPV6h5FAn